Papers
Topics
Authors
Recent
Gemini 2.5 Flash
Gemini 2.5 Flash
97 tokens/sec
GPT-4o
53 tokens/sec
Gemini 2.5 Pro Pro
44 tokens/sec
o3 Pro
5 tokens/sec
GPT-4.1 Pro
47 tokens/sec
DeepSeek R1 via Azure Pro
28 tokens/sec
2000 character limit reached

Molecular Communication-Based Intelligent Dopamine Rate Modulator for Parkinson's Disease Treatment (2403.16564v1)

Published 25 Mar 2024 in cs.ET

Abstract: Parkinson's disease (PD) is a progressive neurodegenerative disease, and it is caused by the loss of dopaminergic neurons in the basal ganglia (BG). Currently, there is no definite cure for PD, and available treatments mainly aim to alleviate its symptoms. Due to impaired neurotransmitter-based information transmission in PD, molecular communication-based approaches can be employed as potential solutions to address this issue. Molecular Communications (MC) is a bio-inspired communication method utilizing molecules for carrying information. This mode of communication stands out for developing bio-compatible nanomachines for diagnosing and treating, particularly in addressing neurodegenerative diseases like PD, due to its compatibility with biological systems. This study presents a novel treatment method that introduces an Intelligent Dopamine Rate Modulator (IDRM), which is located in the synaptic gap between the substantia nigra pars compacta (SNc) and striatum to compensate for insufficiency dopamine release in BG caused by PD. For storing dopamine in the IDRM, dopamine compound (DAC) is swallowed and crossed through the digestive system, blood circulatory system, blood-brain barrier (BBB), and brain extracellular matrix uptakes with IDRMs. Here, the DAC concentration is calculated in these regions, revealing that the required exogenous dopamine consistently reaches IDRM. Therefore, the perpetual dopamine insufficiency in BG associated with PD can be compensated. This method reduces drug side effects because dopamine is not released in other brain regions. Unlike other treatments, this approach targets the root cause of PD rather than just reducing symptoms.

Definition Search Book Streamline Icon: https://streamlinehq.com
References (41)
  1. C. W. Olanow, M. B. Stern, and K. Sethi, “The scientific and clinical basis for the treatment of parkinson disease (2009),” Neurology, vol. 72, no. 21 Supplement 4, pp. S1–S136, 2009.
  2. S. Przedborski, “The two-century journey of parkinson disease research,” Nature Reviews Neuroscience, vol. 18, no. 4, pp. 251–259, 2017.
  3. K. R. Chaudhuri and A. H. Schapira, “Non-motor symptoms of parkinson’s disease: dopaminergic pathophysiology and treatment,” The Lancet Neurology, vol. 8, no. 5, pp. 464–474, 2009.
  4. N. I. Bohnen, R. M. Costa, W. T. Dauer, S. A. Factor, N. Giladi, M. Hallett, S. J. Lewis, A. Nieuwboer, J. G. Nutt, K. Takakusaki, et al., “Discussion of research priorities for gait disorders in parkinson’s disease,” Movement disorders, vol. 37, no. 2, pp. 253–263, 2022.
  5. D. Aarsland, L. Batzu, G. M. Halliday, G. J. Geurtsen, C. Ballard, K. Ray Chaudhuri, and D. Weintraub, “Parkinson disease-associated cognitive impairment,” Nature Reviews Disease Primers, vol. 7, no. 1, p. 47, 2021.
  6. T. N. Tran, T. N. Vo, K. Frei, and D. D. Truong, “Levodopa-induced dyskinesia: clinical features, incidence, and risk factors,” Journal of Neural Transmission, vol. 125, pp. 1109–1117, 2018.
  7. J. Dale, S. L. Schmidt, K. Mitchell, D. A. Turner, and W. M. Grill, “Evoked potentials generated by deep brain stimulation for parkinson’s disease,” Brain stimulation, 2022.
  8. M. Haeri, Y. Sarbaz, and S. Gharibzadeh, “Modeling the parkinson’s tremor and its treatments,” Journal of theoretical biology, vol. 236, no. 3, pp. 311–322, 2005.
  9. M. J. Armstrong and M. S. Okun, “Diagnosis and treatment of parkinson disease: a review,” Jama, vol. 323, no. 6, pp. 548–560, 2020.
  10. M. A. Little, “Smartphones for remote symptom monitoring of parkinson’s disease,” Journal of Parkinson’s Disease, vol. 11, no. s1, pp. S49–S53, 2021.
  11. L. Di Biase, S. Summa, J. Tosi, F. Taffoni, M. Marano, A. Cascio Rizzo, F. Vecchio, D. Formica, V. Di Lazzaro, G. Di Pino, et al., “Quantitative analysis of bradykinesia and rigidity in parkinson’s disease,” Frontiers in neurology, vol. 9, p. 121, 2018.
  12. B. R. Bloem, N. M. de Vries, and G. Ebersbach, “Nonpharmacological treatments for patients with parkinson’s disease,” Movement Disorders, vol. 30, no. 11, pp. 1504–1520, 2015.
  13. Y. Wang, X. Sun, F. Li, Q. Li, and Y. Jin, “Efficacy of non-pharmacological interventions for depression in individuals with parkinson’s disease: A systematic review and network meta-analysis,” Frontiers in Aging Neuroscience, vol. 14, p. 1050715, 2022.
  14. G. Modi, V. Pillay, Y. E. Choonara, V. M. Ndesendo, L. C. du Toit, and D. Naidoo, “Nanotechnological applications for the treatment of neurodegenerative disorders,” Progress in Neurobiology, vol. 88, no. 4, pp. 272–285, 2009.
  15. C. Spuch, O. Saida, and C. Navarro, “Advances in the treatment of neurodegenerative disorders employing nanoparticles,” Recent patents on drug delivery & formulation, vol. 6, no. 1, pp. 2–18, 2012.
  16. M. Biletic, F. H. Juwono, and L. Gopal, “Nanonetworks and molecular communications for biomedical applications,” IEEE Potentials, vol. 39, no. 3, pp. 25–30, 2020.
  17. O. B. Akan, H. Ramezani, T. Khan, N. A. Abbasi, and M. Kuscu, “Fundamentals of molecular information and communication science,” Proceedings of the IEEE, vol. 105, no. 2, pp. 306–318, 2016.
  18. F. Dressler and O. B. Akan, “Bio-inspired networking: from theory to practice,” IEEE Communications Magazine, vol. 48, no. 11, pp. 176–183, 2010.
  19. B. Atakan, O. B. Akan, and S. Balasubramaniam, “Body area nanonetworks with molecular communications in nanomedicine,” IEEE Communications Magazine, vol. 50, no. 1, pp. 28–34, 2012.
  20. B. Atakan and O. B. Akan, “Bio-inspired cross-layer communication and coordination in sensor and vehicular actor networks,” IEEE transactions on vehicular technology, vol. 61, no. 5, pp. 2185–2193, 2012.
  21. J. Végh and Á. J. Berki, “Towards generalizing the information theory for neural communication,” Entropy, vol. 24, no. 8, p. 1086, 2022.
  22. M. Veletić, M. T. Barros, I. Balasingham, and S. Balasubramaniam, “A molecular communication model of exosome-mediated brain drug delivery,” in Proceedings of the Sixth Annual ACM International Conference on Nanoscale Computing and Communication, 2019, pp. 1–7.
  23. O. B. Akan, H. Ramezani, M. Civas, O. Cetinkaya, B. A. Bilgin, and N. A. Abbasi, “Information and communication theoretical understanding and treatment of spinal cord injuries: State-of-the-art and research challenges,” IEEE Reviews in Biomedical Engineering, vol. 16, pp. 332–347, 2021.
  24. F. Dressler and O. B. Akan, “A survey on bio-inspired networking,” Computer networks, vol. 54, no. 6, pp. 881–900, 2010.
  25. D. Malak and O. B. Akan, “Molecular communication nanonetworks inside human body,” Nano Communication Networks, vol. 3, no. 1, pp. 19–35, 2012.
  26. ——, “A communication theoretical analysis of synaptic multiple-access channel in hippocampal-cortical neurons,” IEEE Transactions on communications, vol. 61, no. 6, pp. 2457–2467, 2013.
  27. H. Ramezani and O. B. Akan, “A communication theoretical modeling of axonal propagation in hippocampal pyramidal neurons,” IEEE transactions on nanobioscience, vol. 16, no. 4, pp. 248–256, 2017.
  28. ——, “Impacts of spike shape variations on synaptic communication,” IEEE transactions on nanobioscience, vol. 17, no. 3, pp. 260–271, 2018.
  29. ——, “Importance of vesicle release stochasticity in neuro-spike communication,” in 2017 39th Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC).   IEEE, 2017, pp. 3343–3347.
  30. T. Khan, H. Ramezani, N. A. Abbasi, and O. B. Akan, “Impact of long term plasticity on information transmission over neuronal networks,” IEEE transactions on nanobioscience, vol. 19, no. 1, pp. 25–34, 2019.
  31. A. E. Lang and J. A. Obeso, “Challenges in parkinson’s disease: restoration of the nigrostriatal dopamine system is not enough,” The Lancet Neurology, vol. 3, no. 5, pp. 309–316, 2004.
  32. J. Xie, Z. Shen, Y. Anraku, K. Kataoka, and X. Chen, “Nanomaterial-based blood-brain-barrier (bbb) crossing strategies,” Biomaterials, vol. 224, p. 119491, 2019.
  33. J. Lu, G. Jiang, H. Zhang, B. Qian, H. Zhu, Q. Gu, Y. Yan, J. Z. Liu, B. D. Freeman, L. Jiang, et al., “An artificial sodium-selective subnanochannel,” Science Advances, vol. 9, no. 4, p. eabq1369, 2023.
  34. O. A. A. Alabrahim and H. M. E.-S. Azzazy, “Polymeric nanoparticles for dopamine and levodopa replacement in parkinson’s disease,” Nanoscale advances, vol. 4, no. 24, pp. 5233–5244, 2022.
  35. D. Kilinc and O. B. Akan, “Receiver design for molecular communication,” IEEE Journal on Selected Areas in Communications, vol. 31, no. 12, pp. 705–714, 2013.
  36. M. Kuscu, E. Dinc, B. A. Bilgin, H. Ramezani, and O. B. Akan, “Transmitter and receiver architectures for molecular communications: A survey on physical design with modulation, coding, and detection techniques,” Proceedings of the IEEE, vol. 107, no. 7, pp. 1302–1341, 2019.
  37. M. Pierobon and I. F. Akyildiz, “Diffusion-based noise analysis for molecular communication in nanonetworks,” IEEE Transactions on signal processing, vol. 59, no. 6, pp. 2532–2547, 2011.
  38. D. Deleu, M. G. Northway, and Y. Hanssens, “Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of parkinson’s disease,” Clinical pharmacokinetics, vol. 41, pp. 261–309, 2002.
  39. S. Hacisalihzade, M. Mansour, and C. Albani, “Optimization of symptomatic therapy in parkinson’s disease,” IEEE transactions on biomedical engineering, vol. 36, no. 3, pp. 363–372, 1989.
  40. A. Shamloo, M. Z. Pedram, H. Heidari, and A. Alasty, “Computing the blood brain barrier (bbb) diffusion coefficient: A molecular dynamics approach,” Journal of Magnetism and Magnetic Materials, vol. 410, pp. 187–197, 2016.
  41. E. Syková and C. Nicholson, “Diffusion in brain extracellular space,” Physiological reviews, vol. 88, no. 4, pp. 1277–1340, 2008.
User Edit Pencil Streamline Icon: https://streamlinehq.com
Authors (2)
  1. Elham Baradari and (1 paper)
  2. Ozgur B Akan (129 papers)

Summary

We haven't generated a summary for this paper yet.

Ai Sparkles Streamline Icon: https://streamlinehq.com Summarize Now